Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
Ключови думи
Резюме
Описание
It is well recognized that sickle cell disease (SCD) is characterized by a vasculopathy, with involvement of multiple organs including the brain, lung, spleen, and kidney. This results in multiple clinical complications, including ischemic stroke, pulmonary hypertension, autosplenectomy, as well as albuminuria and chronic renal disease. Several recent studies have confirmed the association of both albuminuria and renal dysfunction with echocardiographically-defined pulmonary hypertension and other vasculopathic complications in SCD, suggesting that they may share a similar pathophysiology. Despite the high prevalence of albuminuria in patients with SCD and the known association of renal failure with increased mortality, the pathophysiology and treatment of albuminuria in this setting remain poorly defined.
The treatment options for nephropathy in SCD are limited. Although Angiotensin converting enzyme (ACE) inhibitors are the "standard of care" in the treatment of patients with proteinuria, there are to date no controlled, long-term studies confirming their efficacy and safety in this setting.
In this study, the investigators will evaluate the efficacy and safety of atorvastatin in SCD patients. At the completion of this trial, the investigators will have an improved understanding of the contribution of endothelial dysfunction to the pathophysiology of albuminuria in SCD. If the data support the hypothesis that atorvastatin is safe and effective in this population, the investigators plan on carrying out adequately powered studies to more definitively evaluate its safety and efficacy in the treatment and/or prevention of albuminuria in SCD.
Дати
| Последна проверка: | 10/31/2018 |
| Първо изпратено: | 11/08/2012 |
| Очаквано записване подадено: | 11/18/2012 |
| Първо публикувано: | 11/25/2012 |
| Изпратена последна актуализация: | 03/15/2020 |
| Последна актуализация публикувана: | 03/17/2020 |
| Дата на първите подадени резултати: | 12/12/2018 |
| Дата на първите подадени резултати от QC: | 01/13/2019 |
| Дата на първите публикувани резултати: | 02/04/2019 |
| Действителна начална дата на проучването: | 08/31/2013 |
| Приблизителна дата на първично завършване: | 01/08/2018 |
| Очаквана дата на завършване на проучването: | 01/08/2018 |
Състояние или заболяване
Интервенция / лечение
Drug: Atorvastatin
Drug: Placebo
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: Atorvastatin, then Placebo Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. | |
| Placebo Comparator: Placebo, Then Atorvastatin Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks. |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: 1. Sickle cell anemia (HbSS) or Sickle-beta0 thalassemia (HbS-beta0thal) between ages of 18 and 60; 2. albuminuria (micro- or macroalbuminuria, defined as =/> 30mg/g creatinine); 3. serum alanine aminotransferase (ALT) 4. platelet count > 150,000 cu/mm; 5. normal baseline coagulation profile (PT, International Normalized Ratio (INR), and PTT); 6. non-crisis, steady state with no severe pain episodes during the preceding 4 weeks, and no documented infection in the 2 weeks prior to enrollment; 7. ability to understand the requirements of the study; 8. if a woman of childbearing potential, must use an adequate method of contraception; and 9. if receiving hydroxyurea, ACE inhibitors or angiotensin blockers (ARB), should be on a stable dose for at least 3 months. Exclusion Criteria: 1. hypersensitivity to any component of atorvastatin, or history of adverse reaction to statins; 2. pregnant or breastfeeding; 3. on statin therapy; 4. history of metastatic cancer; 5. current history of alcohol abuse; 6. history of diabetes mellitus or poorly controlled systemic hypertension; 7. end-stage renal disease; 8. total cholesterol level < 80 mg/dL and LDL cholesterol > 130 mg/dL; 9. on a chronic transfusion program; 10. ingested any investigational drugs within the past 4 weeks; 11. prior history of any myopathy; 12. allergy to nitroglycerin; 13. taking any of the following drugs: phosphodiesterase-5 inhibitors (e.g., sildenafil), cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g., cyclosporine, protease inhibitors), macrolide antibiotics (e.g., clarithromycin, erythromycin), fibric acid derivatives (e.g. gemfibrozil), niacin, colchicines, antifungal agents (azole derivatives), amiodarone, danazol, daptomycin, diltiazem, verapamil, eltrombopag, everolimus, fosphenytoin, or lanthanum. Patients will also be encouraged to avoid grape fruit juice and red yeast rice for the duration of the study. Atorvastatin is contraindicated during pregnancy and breast-feeding. |
Резултат
Първични изходни мерки
1. Change From Baseline to Week 6 in Endothelial Function [Baseline, 6 weeks]
Вторични изходни мерки
1. Change From Baseline to Week 6 in Plasma Markers of Endothelial Activation [Baseline, 6 weeks]
2. Change From Baseline to Week 6 in Heme Oxygenase Activity [Baseline, 6 weeks]
3. Change From Baseline to Week 6 in Plasma Levels of Soluble Fms-like Tyrosine Kinase-1 (sFLT-1) [Baseline, 6 weeks]
4. Change From Baseline to Week 6 in Monocyte Activation [Baseline, 6 weeks]
5. Change From Baseline to Week 6 in Renal Function [Baseline, 6 weeks]
6. Occurrence of Adverse Events. [Continuously from randomization through end of study]
7. Abnormal Physical Findings. [Baseline, 2, 4, and 6 weeks during treatment, and at follow-up.]
8. Change From Baseline to Week 6 in Rho/Rho Kinase Activity [Baseline, 6 weeks]
9. Change From Baseline to Week 6 in Plasma Levels of Vascular Endothelial Growth Factor (VEGF) [Baseline, 6 weeks]
10. Mean Change From Baseline to Week 6 in Absolute Cell Counts [Baseline, 6 weeks]
11. Change From Baseline to Week 6 in Tissue Factor (TF) Expression [Baseline, 6 weeks]
12. Change From Baseline to Week 6 in TF-mediated sFLT Release From Monocytes [Baseline, 6 weeks]
13. Change From Baseline to Week 6 in Tricuspid Regurgitant (TR) Jet. [Baseline, Week 6]
